ARTICLE FROM KACTUS
IL-23: A Key Target for the Treatment of Immune-Mediated Inflammatory Diseases
In KACTUS ’s recent feature, Lauren He from KACTUS introduced a comprehensive overview of Interleukin-23 (IL-23) and its role in driving immune-mediated inflammatory diseases (IMIDs) such as psoriasis, Crohn’s disease, and ulcerative colitis.
*All products listed on this site and sold through LAB-A-PORTER Limited are for research use only (RUO). Not for human use. Not for therapeutic or diagnostic use.
ABOUT KACTUS
Provides quality recombinant proteins and enzymes that accelerate therapeutic development
Founded in 2018, KACTUS is a leading manufacturer of recombinant proteins and enzymes, providing both off-the-shelf products and custom protein services. Their extensive catalog includes over 3,000 recombinant proteins, featuring antibody drug targets, cytokines, transmembrane proteins, MHC monomers and tetramers, immune checkpoint proteins, biotinylated proteins, and more. They also offer AAV titration ELISA kits, GMP-grade gene editing enzymes, and other GMP enzymes. All their products undergo rigorous testing for purity and bioactivity to ensure quality performance and consistency. KACTUS is ISO 13485:2016 certified and operates state-of-the-art facilities, including a 10,000 sq. meter GMP-grade manufacturing site.